A 4-week, dose-ranging, double-blind, randomized, placebo-controlled, parallel-group study to assess the safety and efficacy of APD356 in obese patients
Phase of Trial: Phase II
Latest Information Update: 22 Dec 2006
At a glance
- Drugs Lorcaserin (Primary)
- Indications Obesity
- Focus Therapeutic Use
- 08 Oct 2005 New trial record.